Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal - 10/04/2023
Date Insider Type Main position Quantity % Market Cap. Importance
10/4/23 Free

Executive/Senior Manager

400,000 0.6684%
1/2/23 Free

Chief Technology Officer

400,000 0.6686%
1/2/23 Free

Chief Operating Officer

400,000 0.6686%
Change 5-day change 1-year change 3-year change Capi.($)
-13.39%-23.18% - - 2.95M
-2.11%-1.68%+43.40%+95.58% 66.93B
+0.94%-1.04%+34.86%+75.31% 61.97B
-2.21%+2.41%-10.65%+379.55% 28.26B
+4.55%+1.36%+26.52%+17.28% 24.59B
+1.56%+0.59%+1.39%-12.80% 24.3B
+1.05%-1.07%+19.06%-21.85% 19.41B
-3.03%-2.29%+181.72%+333.47% 16.77B
+3.44%-1.88%-5.46%+547.21% 14.18B
+4.96%+8.22%-1.27%+879.06% 14B
Average -0.55%-2.95%+32.17%+254.76% 30.05B
Weighted average by Cap. +0.23%-2.83%+32.44%+174.32%
Logo Aravive, Inc.
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Employees
23
  1. Stock Market
  2. Stocks
  3. ARAV Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!